结肠癌qBiomarker体细胞突变PCR芯片 Colon Cancer qBiomarker Mutation PCR Array

“英拜为您实验加速”
技术服务网址：http://www.yingbio.com/
服务热线：400-696-6643、 18019265738
邮箱：daihp@yingbio.com 、 huizhang1228@foxmail.com

Colon Cancer qBiomarker Mutation PCR Array

结肠癌qBiomarker体细胞突变PCR芯片
 

Product	Species	Technology	Cat. No.
Colon Cancer qBiomarker Mutation PCR Array	Human	Somatic Mutation	SMH-021A

The Human Colon Cancer qBiomarker Somatic Mutation PCR Array is a translational research tool that allows rapid, accurate, and comprehensive profiling of the top somatic mutations in human colon cancer samples in the following genes: APC, BRAF, CTNNB1/beta-catenin, FBXW7, KRAS, PIK3CA, SRC, and P53. These mutations warrant extensive investigation to enhance the understanding of carcinogenesis and identify potential drug targets. Numerous research studies have demonstrated the utility of individual and multiple somatic mutation status information in identifying key signaling transduction disruptions. For example, the mutation status of the EGFR and KRAS genes can predict the physiological response to certain drugs targeting these molecules. The Human Colon Cancer qBiomarker Somatic Mutation PCR Array, with its comprehensive content coverage, is designed for the study of mutations in the context of colon cancer and has the potential for discovery and verification of drug target biomarkers for this cancer type and other cancer types in which these mutations have been identified. This array includes 86 DNA sequence mutation assays designed to detect the most frequent, functionally verified, and biologically significant mutations in human colon cancer. These mutations were chosen from curated, comprehensive somatic mutation databases and peer-reviewed scientific literature, and represent the most frequently recurring somatic mutations compiled from over 29,000 colon cancer samples. The simplicity of the product format and operating procedure allows routine somatic mutation profiling in any research laboratory with access to real-time PCR instruments.
 
结肠癌qBiomarker体细胞突变PCR芯片是一个翻译研究的工具,允许快速、准确、全面的分析在人类结肠癌样本中前体细胞的基因突变:APC,BRAF,CTNNB1 /β-连环蛋白FBXW7, KRAS, PIK3CA, SRC, and P53。这些突变保证广泛的研究,以提高致癌作用的理解和鉴定潜在的药物靶点。已有许多研究通过单个和多个体细胞突变状态信息鉴定关键信号转导中断。例如，EGFR和KRAS基因的突变状态可以预测某些药物针对这些分子的生理反应。人类结肠癌qBiomarker体细胞突变PCR芯片以其全面的内容覆盖范围，用于研究结肠癌背景下的基因突变,有可能发现和鉴定结肠癌和这些突变已确定的其他癌症的药物靶标。这个芯片包含86个DNA突变序列用于检测最频繁的、能性验证、在人类结肠癌症中有生物学意义的突变。这些突变的选择根据全面的体细胞突变数据库和同行评审的科学文献，来自29,000多个结肠癌样本发生最频繁重复编译的体细胞突变。简单的产品模式和操作程序让任何一个具备实时定量PCR仪的实验室都可进行常规的体细胞突变分析。
 
APC: 34 Assays
The most commonly detected APC inactivation mutations are mainly composed of truncation mutations (due to nonsense mutations and frameshift mutations) and point mutations between codons 1250 and 1578.
BRAF: 1 Assay
In colon cancer, the BRAF mutation that leads to increased kinase activity, p. V600E mutation, is the most important to test.
CTNNB1: 5 Assays
The most frequently detected CTNNB1/beta-catenin mutations result in abnormal signaling in the WNT signaling pathway. The mutated codons are mainly several serine/threonine residues targeted for phosphorylation by GSK-3beta.
FBXW7: 1 Assay
The mutations queried by these assays lay in either the third or fourth repeat of the protein's WD40 domain, typically involved in protein-protein interactions.
KRAS: 17 Assays
The mutation assays include the most frequently occurring mutations in KRAS codons 12, 13, and 61. Mutations at these positions result in reduced intrinsic GTPase activity and/or cause KRAS to become unresponsive to RasGAP.
PIK3CA: 7 Assays
The most frequently occurring PIK3CA mutations mainly belong to two classes: gain-of-function kinase domain activating mutations and helical domain mutations that mimic activation by growth factors.
SRC: 1 Assay
SRC is a proto-oncogene and a tyrosine-protein kinase that plays a role in the regulation of embryonic development and cell growth. Mutations in this gene could be involved in the malignant progression of colon cancer.
TP53: 20 Assays
The most frequently detected somatic mutations in TP53 are largely composed of DNA-binding domain mutations which disrupt either DNA binding or protein structure.

工作原理：

Overview of the qBiomarker Somatic Mutation PCR Array / Assay Protocol

 

Overview of the qBiomarker Somatic Mutation PCR Array / Assay Protocol.
The procedure involves DNA extraction (QIAGEN QIAamp DNA Mini Kit or FFPE Tissue Kit is recommended), an optional amplification (QIAGEN REPLI-g kit or REPLI-g UltraFast kit is recommended) step for DNA isolated from fresh samples, qPCR detection on qBiomarker Somatic Mutation PCR Arrays or Assays, and data analysis (using the qBiomarker Somatic Mutation Data Analysis Template). An optional DNA sample QC step immediately before the detection array or assay setup allows the user to qualify the DNA samples.

Principle of Mutant Discrimination with ARMS®